Table 3.
Baseline characteristics of subjects selected for stratified analyses
| Variables | GCQID groupa (n=23) |
Placebo groupa (n=25) |
P-value |
|---|---|---|---|
| Age (years) | 51.5±1.7 | 50.6±1.4 | 0.702 |
| Sex (male/female) | 9/14 | 12/13 | 0.536 |
| Height (cm) | 162.3±1.7 | 163.8±1.7 | 0.527 |
| Body weight (kg) | 63.1±2.8 | 62.9±2.3 | 0.956 |
| Body mass index (kg/m2) | 23.8±0.7 | 23.4±0.7 | 0.696 |
| Systolic blood pressure (mmHg) | 131.1±3.6 | 126.6±3.2 | 0.352 |
| Diastolic blood pressure (mmHg) | 82.7±2.5 | 82.4±2.5 | 0.924 |
| Heart rate (beats/min) | 72.0±2.3 | 76.7±2.3 | 0.153 |
| Normal walking speed (m/s) | 1.26±0.04 | 1.25±0.03 | 0.957 |
| Knee-extensor strength (% body weight)b | 93.4±6.7 | 81.5±7.6 | 0.248 |
| JOA criteria aggregate scores (points) | 178.9±2.0 | 175.4±2.9 | 0.522 |
| VAS score for pain on walking (mm) | 33.3±4.3 | 24.5±3.0 | 0.103 |
| Average daily steps walked in a week (steps) | 6,221±510 | 6,386±599 | 0.837 |
| K–L grades (0, I, II) | 6, 14, 3 | 7, 12, 6 | 0.563 |
Notes:
a
All values except sex and K–L grade are expressed as mean ± standard error.
b
Knee-extensor strength was measured in both knees and expressed as total strength of both knees.
Abbreviations: GCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, and vitamin D; JOA, Japanese Orthopaedic Association; K–L, Kellgren–Lawrence; VAS, visual analog scale.